Study of metformin in polycystic ovary syndrome

Heeta R. Mehta, Sushma R. Shah, Ami V. Mehta, Payal P. Panchal


Background: Objective of the study was to measure the efficacy and safety of insulin sensitizing drug metformin in reversing the metabolic and endocrine disturbances in fifty women with polycystic ovarian disease.

Methods: The study was performed on 57 women with polycystic ovarian syndrome (PCOS) in the outpatient department of obstetrics and gynaecology, V. S. General Hospital, Ahmedabad. Metformin 500 mg thrice daily was given until the cysts disappeared which was taken as the end point of the study. Follicular studies were done to check the effect of metformin on ovulation. Significance was tested by paired t test and p value calculated.

Results: Metformin was found effective in regressing polycystic changes in ovary, regularization of menstrual cycles and improving ovulation.

Conclusions: The present study shows that metformin has a beneficial role in effective management of PCOS.



PCOS, Cysts, Metformin

Full Text:



Kollmann M, Martins WP, Raine-Fenning N. Terms and thresholds for the ultrasound evaluation of the ovaries in women with hyperandrogenic anovulation. Hum Reprod Update. 2014;20(3):463-4.

USMLE-Rx. MedIQ Learning, LLC. Stein-Leventhal syndrome, also known as polycystic ovary syndrome (PCOS), is a disorder characterized by hirsutism, obesity, and amenorrhea because of luteinizing hormone-resistant cystic ovaries. 2014.

Rowland AS, Baird DD, Long S, Wegienka G, Harlow SD, Alavanja M, Sandler DP. Influence of medical conditions and lifestyle factors on the menstrual cycle. Epidemiology. 2002;13(6):668-74.

Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005;26(2):251-82.

Atiomo W, Pearson S, Shaw S, Prentice A, Dubbins P. Ultrasound criteria in the diagnosis of polycystic ovary syndrome (PCOS). Ultrasound in Medicine & Biology. 2000;26(6):977-80.

Patel K, Coffler MS, Dahan MH, Malcom PJ, Deutsch R, Chang RJ. Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2004;60(1):67-74.

Burghen GA, Givens JR, Kitabchi AE, correlation of hyperandrogenism with hyperinsulinemia in polycystic ovarian disease. Clin Endocrinol Metab. 1980;50:113-6.

Franks S, Hardy K. What causes anovulation in polycystic ovary syndrome? Curr Opin Endocrine Metab Res. 2020;12:59-65.

Gorry A, White DM, Franks S. Infertility in polycystic ovary syndrome. Endocrine. 2006;30:27-33.

Lee AT, Zane LT. Dermatologic Manifestations of Polycystic Ovary Syndrome. Am J Clin Dermatol. 2007;8:201-19.

Wild R. Dyslipidemia in PCOS. Steroids. 2012;77(4):295-9.

Macut D, Mladenović V, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, Rašić-Marković A, Milutinović DV, Andrić Z. Hypertension in Polycystic Ovary Syndrome: Novel Insights. Curr Hypertens Rev. 2020;16(1):55-60.

Bastard J, Pironi L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes/Metabolism Research and Reviews. 2000;16(3):192-201.

Velaque EM, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol. 1997;90:392-5.

Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin – induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with polycystic ovary syndrome. Metabolism. 1999;8:511-9.

Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85(1):139-46.